Search

Displaying results 2331 - 2340 of 6076 in total
  1. Drug

    Betazole

    go.drugbank.com/drugs/DB00272
    Approved

    A histamine H2 agonist used clinically to test gastric secretory function.

    Categories: Tests for Gastric Secretion
  2. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. … [L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins.

  3. Drug

    Chloropyramine

    go.drugbank.com/drugs/DB08800
    Investigational

    It is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use
  4. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    to be approved for this specific patient population. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  5. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  6. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

  7. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … [L45156] Dostarlimab is currently under investigation for the treatment of rectal cancers with mismatch repair deficiency.

  8. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: BLACKMORES teen multi for GIRLS capsule
  10. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. … Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women